Pseudomembranous enterocolitis: Difference between revisions

Jump to navigation Jump to search
 
No edit summary
Line 1: Line 1:
__NOTOC__
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name          = Pseudomembranous colitis |
   Name          = Pseudomembranous colitis |
Line 8: Line 9:
   OMIM          = |
   OMIM          = |
   MedlinePlus    = 000259 |
   MedlinePlus    = 000259 |
  eMedicineSubj  = med |
  eMedicineTopic = 1942 |
   DiseasesDB    = 2820 |
   DiseasesDB    = 2820 |
   MeshID        = D004761 |
   MeshID        = D004761 |
Line 15: Line 14:
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
{{EH}}
{{see also|Clostridium difficile}}


==Overview==
==Overview==
Line 86: Line 81:
==Prevention==
==Prevention==
A [[randomized controlled trial]] using a probiotic drink containing ''Lactobacillus casei'', ''L bulgaricus'', and ''Streptococcus thermophilus'' was reported to have some efficacy. This study was sponsored by the company that produces the drink studied <ref name="pmid17604300">{{cite journal |author=Hickson M, D'Souza AL, Muthu N, ''et al'' |title=Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial |journal=BMJ |volume=335 |issue=7610 |pages=80 |year=2007 |pmid=17604300 |doi=10.1136/bmj.39231.599815.55}}</ref>. Although intriguing, several other studies have been unable to demonstrate any benefit of oral supplements of similar bacteria at preventing CDAD.
A [[randomized controlled trial]] using a probiotic drink containing ''Lactobacillus casei'', ''L bulgaricus'', and ''Streptococcus thermophilus'' was reported to have some efficacy. This study was sponsored by the company that produces the drink studied <ref name="pmid17604300">{{cite journal |author=Hickson M, D'Souza AL, Muthu N, ''et al'' |title=Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial |journal=BMJ |volume=335 |issue=7610 |pages=80 |year=2007 |pmid=17604300 |doi=10.1136/bmj.39231.599815.55}}</ref>. Although intriguing, several other studies have been unable to demonstrate any benefit of oral supplements of similar bacteria at preventing CDAD.
==Related Chapters==
*[[Clostridium difficile]]


==References==
==References==
Line 93: Line 91:
*[http://www.thebody.com/pwa/sacc.html PWA Health Group - Saccharomyces boulardii Info Sheet]
*[http://www.thebody.com/pwa/sacc.html PWA Health Group - Saccharomyces boulardii Info Sheet]


{{SIB}}
{{Bacterial diseases}}
{{Bacterial diseases}}
{{Gastroenterology}}
{{Gastroenterology}}

Revision as of 19:04, 4 August 2012

Template:DiseaseDisorder infobox

WikiDoc Resources for Pseudomembranous enterocolitis

Articles

Most recent articles on Pseudomembranous enterocolitis

Most cited articles on Pseudomembranous enterocolitis

Review articles on Pseudomembranous enterocolitis

Articles on Pseudomembranous enterocolitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pseudomembranous enterocolitis

Images of Pseudomembranous enterocolitis

Photos of Pseudomembranous enterocolitis

Podcasts & MP3s on Pseudomembranous enterocolitis

Videos on Pseudomembranous enterocolitis

Evidence Based Medicine

Cochrane Collaboration on Pseudomembranous enterocolitis

Bandolier on Pseudomembranous enterocolitis

TRIP on Pseudomembranous enterocolitis

Clinical Trials

Ongoing Trials on Pseudomembranous enterocolitis at Clinical Trials.gov

Trial results on Pseudomembranous enterocolitis

Clinical Trials on Pseudomembranous enterocolitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pseudomembranous enterocolitis

NICE Guidance on Pseudomembranous enterocolitis

NHS PRODIGY Guidance

FDA on Pseudomembranous enterocolitis

CDC on Pseudomembranous enterocolitis

Books

Books on Pseudomembranous enterocolitis

News

Pseudomembranous enterocolitis in the news

Be alerted to news on Pseudomembranous enterocolitis

News trends on Pseudomembranous enterocolitis

Commentary

Blogs on Pseudomembranous enterocolitis

Definitions

Definitions of Pseudomembranous enterocolitis

Patient Resources / Community

Patient resources on Pseudomembranous enterocolitis

Discussion groups on Pseudomembranous enterocolitis

Patient Handouts on Pseudomembranous enterocolitis

Directions to Hospitals Treating Pseudomembranous enterocolitis

Risk calculators and risk factors for Pseudomembranous enterocolitis

Healthcare Provider Resources

Symptoms of Pseudomembranous enterocolitis

Causes & Risk Factors for Pseudomembranous enterocolitis

Diagnostic studies for Pseudomembranous enterocolitis

Treatment of Pseudomembranous enterocolitis

Continuing Medical Education (CME)

CME Programs on Pseudomembranous enterocolitis

International

Pseudomembranous enterocolitis en Espanol

Pseudomembranous enterocolitis en Francais

Business

Pseudomembranous enterocolitis in the Marketplace

Patents on Pseudomembranous enterocolitis

Experimental / Informatics

List of terms related to Pseudomembranous enterocolitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pseudomembranous colitis is an infection of the colon often, but not always, caused by the bacterium Clostridium difficile. Still, the expression "C. diff colitis" is used almost interchangeably with the more proper term of pseudomembranous colitis. The illness is characterized by offensive-smelling diarrhea, fever, and abdominal pain. It can be severe, causing toxic megacolon, or even fatal.

Mechanism of Disease

The use of broad-spectrum antibiotics such as clindamycin and cephalosporins causes the normal bacterial flora of the bowel to be altered. In particular, when the antibiotic kills off other, competing bacteria in the intestine, any bacteria remaining will have less competition for space and nutrients there. The net effect is to permit much more extensive growth than normal of certain bacteria. Clostridium difficile is one such type of bacteria. In addition to proliferating in the bowel, the C. diff also elaborates a toxin. It is this toxin that is responsible for the diarrhea which characterizes pseudomembranous colitis.

Risk factors and epidemiology

In most cases a patient presenting with pseudomembranous colitis has recently been on antibiotics. Antibiotics disturb the normal bowel bacterial flora. Clindamycin is the antibiotic classically associated with this disorder, but any antibiotic can cause the condition. Even though they are not particularly likely to cause pseudomembranous colitis, but, rather, due to their very frequent use, cephalosporin antibiotics (such as cefazolin and cephalexin) account for a large percentage of cases. Diabetics and the elderly are also at increased risk, although half of cases are not associated with risk factors.

Other risk factors include increasing age and recent major surgery. There is some evidence that proton pump inhibitors are a risk factor for pseudomembranous colitis,[1] but others question whether this is a false association or statistical artifact (increased PPI use is itself a marker of increased age and co-morbid illness).[2]; indeed, one large case-controlled study showed that PPI's are not a risk factor.[3] Recently, evidence has emerged to suggest that the use of ciprofloxacin (in addition to a primary causative antibiotic such as clindamycin) is associated with increased mortality in patients with pseudomembranous colitis.

Clinical Features

As noted above, pseudomembranous colitis is characterized by diarrhea, abdominal pain, and fever. Usually, the diarrhea is non-bloody, although blood may be present if the affected individual is taking blood thinners or has an underlying lower bowel condition such as hemorrhoids. Abdominal pain is almost always present and may be severe. So-called "peritoneal" signs (e.g. rebound tenderness) may be present. "Constitutional" signs such as fever, fatigue, and loss of appetite are prominent. In fact, one of the main ways of distinguishing pseudomembranous colitis from other antibiotic-associated diarrheal states is that patients with the former are sick. That is, they are often prostrate, lethargic, and generally look unwell. Their "sick" appearance tends to be paralleled by the results of their blood tests which often show anemia, an elevated white blood cell count, and low serum albumin.

Diagnosis

In order to make the diagnosis, it is, of course, essential that the treating physician be aware of any recent antibiotic usage. The disease may occur as late as one or two months after the use of antibiotics. Although there is some relationship between dose/duration of antibiotic and likelihood of developing pseudomembranous colitis, it may occur even after a single dose of antibiotic. In fact, the use of single-dose antibiotic is a common practice in surgical patients for whom such a treatment is often given just prior to surgery in order to prevent infection at the surgical site. Hence, even though unlikely to cause pseudomembranous colitis on a per-case basis, single-dose antibiotic treatment, by virtue of the large number of patients receiving such, is an important cause of pseudomembranous colitis.

Prior to the advent of tests to detect the Clostridium difficile toxin, the diagnosis was most often made by colonoscopy or sigmoidoscopy. The appearance of "pseudomembranes" on the surface of the colon or rectum is diagnostic of the condition. The pseudomembranes are composed of inflammatory debris, white blood cells, etc.

Although colonoscopy and sigmoidoscopy are still employed, stool testing for the presence of Clostridium difficile toxin is now often the first-line diagnostic appraoach. Usually, only two toxins are tested for - Toxin A and Toxin B - but the organism produces at least several others. It is, perhaps, for this reason that some people who seem to have pseudomembranous colitis (i.e. a history of antibiotic use, non-bloody diarrhea, and the presence of pseudomembranes seen on colonoscopy) do not have detectable C. diff toxin in their stool.

X-ray

  • Plain radiographic findings in including colonic ileus, small bowel ileus, ascites, and nodular haustral thickening .
  • Thumbprinting (unusual, wide transverse bands associated with thickening of the haustral folds) and gaseous distention of the colon have also been identified.

CT

  • Common CT findings include wall thickening, low-attenuation mural thickening corresponding to mucosal and submucosal edema, the accordion sign, the target sign, double halo sign, pericolonic stranding, and ascites.
    • The target sign, which consists of two or three concentric rings of different attenuation, indicates mucosal hyperemia and submucosal edema or inflammation. The rings of varying attenuation are best appreciated during the arterial phase of enhancement.
    • The accordion sign is seen when orally administered contrast material becomes trapped between markedly thickened haustral folds, giving the appearance of alternating bands of high attenuation (contrast material) and low attenuation (edematous haustra). This sign is highly suggestive of PMC, although it is usually seen only in advanced cases.

Treatment

The disease is usually treated with metronidazole (400 mg every 8 hours). Oral vancomycin (125 mg every 6 hourly) is an alternative but, due to its cost, is often reserved for those patients who have experienced a relapse after a course of metronidazole (a common outcome). Vancomycin treatment also presents the risk of the development of vancomycin resistant enterococcus, and its use for the treatment of C. Difficile infection is now questioned by some institutions. Occasionally metronidazole has been associated with the development of pseudomembranous colitis. In these cases metronidazole is still an effective treatment, since the cause of the colitis is not the antibiotic, but rather the change in bacterial flora from a previous round of antibiotics.

Adjunctive therapy may include cholestyramine, a bile acid resin that can be used to bind C. difficile toxin.

Saccharomyces boulardii (a yeast) has been shown in one small study of 124 patient to reduce the recurrence rate of pseudomembranous colitis.[4] A number of mechanisms have been proposed to explain this effect.

Fecal bacteriotherapy, a procedure related to probiotic research, has been suggested as an alternative cure for the disease. It involves infusion of bacterial flora acquired from the feces of a healthy donor in an attempt to repair the bacterial imbalance responsible for the recurring nature of the infection.

Anecdotal evidence suggests kefir can help treat pseudomembranous colitis.

If antibiotics do not control the infection the patient may require a colectomy (removal of the colon) for treatment of the colitis.

Prevention

A randomized controlled trial using a probiotic drink containing Lactobacillus casei, L bulgaricus, and Streptococcus thermophilus was reported to have some efficacy. This study was sponsored by the company that produces the drink studied [5]. Although intriguing, several other studies have been unable to demonstrate any benefit of oral supplements of similar bacteria at preventing CDAD.

Related Chapters

References

  1. Dial S, Delaney C, Schneider V, Suissa S. (2006). "Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy". CMAJ. 175 (7): 745&ndash, 48. doi:10.1503/cmaj.060284.
  2. Pépin J, Saheb N, Coulombe M; et al. (2005). "Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea: a cohort study during an epidemic in Quebec". Clin Infect Dis. 41: 1254&ndash, 60. doi:10.1086/496986. PMID 16206099.
  3. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006). "Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study". Clin Infect Dis. 43 (10): 1272&ndash, 6. PMID 17051491.
  4. McFarland LV, Surawicz CM, Greenberg RN; et al. (1994). "A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease". JAMA. 271 (24): 1913&ndash, 18. PMID 8201735.
  5. Hickson M, D'Souza AL, Muthu N; et al. (2007). "Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial". BMJ. 335 (7610): 80. doi:10.1136/bmj.39231.599815.55. PMID 17604300.

External links

Template:Bacterial diseases Template:Gastroenterology

de:Antibiotikaassoziierte Kolitis hr:Pseudomembranozni kolitis nl:Pseudomembraneuze colitis no:Pseudomembranøs kolitt


Template:WikiDoc Sources